Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 28, 2013; 19(4): 575-580
Published online Jan 28, 2013. doi: 10.3748/wjg.v19.i4.575
Table 1 SHP-2 expression in 83 paired gastric cancers and adjacent normal mucus and SHP-2 by Helicobacter pylori infection in gastric cancer groups n (%)
H-score
Median H-score (quartile)P value
01-99100-200201-300
Cancer (n = 83)10 (12.0)21 (25.3)27 (32.5)25 (30.1)160 (40-210)< 0.001
Control (n = 83)41 (49.4)15 (18.1)21 (25.3)6 (7.2)20 (0-160)
Positive (n = 67)8 (11.9)8 (11.9)24 (35.8)27 (40.3)180 (120-270)0.401
Negative (n = 33)1 (3.0)10 (30.3)11 (33.3)11 (33.3)160 (85-240)
Table 2 SHP-2 expressions and clinical characteristics of 305 gastric cancer patients
H-score, n (%)
Median H-score (quartile)P value
01-99100-200201-300
Sex
Male (n = 233)16 (6.9)44 (18.9)79 (33.9)94 (40.3)160 (100-240)0.82
Female (n = 72)4 (5.6)8 (11.1)36 ( 50.0)24 (33.3)160 (140-240)
Age
≤ 60 yr (n = 129)9 (7.0)23 (17.8)50 (38.8)47 (36.4)160 (110-240)0.92
> 60 yr (n = 176)11 (6.3)29 (16.5)65 (36.9)71 (40.3)180 (110-240)
Differentiation
Well (n = 6)0 (0)1 (16.7)1 (16.7)4 (66.7)225 (155-270)0.43
Moderate (n = 114)8 (7.0)20 (17.5)41 (36.0)45 (39.5)160 (115-240)
Poor (n = 185)12 (6.5)31 (16.8)73 (39.5)69 (37.3)160 (120-240)
Lymph-vascular invasion
No (n = 142)9 (6.3)22 (15.5)54 (38.0)57 (40.1)160 (120-240)0.89
Yes (n = 163)11 (6.7)30 (18.4)61 (37.4)61 (37.4)160 (100-240)
Nerve invasion
No (n = 184)14 (7.6)30 (16.3)70 (38.0)70 (38.0)160 (120-240)0.40
Yes (n = 121)6 (5.0)22 (18.2)45 (37.2)48 (39.7)160 (120-240)
TNM staging
I (n = 25)0 (0)3 (12.0)12 (48.0)10 (40.0)180 (140-270)0.34
II (n = 50)4 (8.0)8 (16.0)13 (26.0)25 (50.0)195 (115-270)
III (n = 194)14 (7.2)32 (16.5)77 (39.7)71 (36.6)160 (120-240)
IV (n = 36)0 (0)7 (20.6)14 (41.2)13 (38.2)160 (100-242)
Invasion
T1 (n = 9)0 (0)0 (0)4 (44.4)5 (55.6)240 (170-270)0.34
T2 (n = 37)1 (2.7)7 (18.9)18 (48.6)11 (29.7)160 (120-225)
T3 (n = 225)19 (8.4)38 (16.9)79 (35.1)89 (39.6)160 (100-240)
T4 (n = 34)0 (0)7 (20.6)14 (41.2)13 (38.2)160 (120-248)
Lymph node metastases
N0 (n = 66)3 (4.5)10 (15.2)23 (34.8)30 (45.5)180 (140-270)0.17
N1 (n = 94)7 (7.4)15 (16.0)31 (33.0)41 (43.6)180 (120-240)
N2 (n = 79)3 (3.8)15 (19.0)39 (49.4)22 (27.8)160 (120-210)
N3 (n = 66)7 (10.6)12 (18.2)22 (33.3)25 (37.9)160 (100-270)
Distant metastasis
No (n = 266)18 (6.8)43 (16.2)101(38.0)104 (39.1)170 (120-240)0.52
Yes (n = 39)2 (5.1)9 (23.1)14 (35.9)14 (35.9)160 (100-240)
Survival
Survived (n = 180)12 (6.7)28 (15.6)69 (38.3)71 (39.4)180 (120-240)0.77
Died (n = 125)8 (6.4)24 (19.2)46 (36.8)47 (37.6)160 (100-240)
Table 3 Multivariate analyses for disease-specific survival
RR (95% CI)P value
SHP-2 expression
H-score (201-300) (n = 118)
H-score (100-200) (n = 115)0.99 (0.63-1.56)0.98
H-score (1-99) (n = 52)1.08 (0.72-1.64)0.70
Negative (0) (n = 20)1.04 (0.49-1.67)0.82
Tumor node metastasis staging
I (n = 25)
II (n = 51)1.87 (0.52-6.79)0.34
III (n = 195)3.94 (1.22-12.74)0.02
IV (n = 34)13.63 (4.04-46.06)0.00
Lymph-vascular invasion
Yes (n = 142)
No (n = 163)1.61 (1.09-2.37)0.02